Harrow, Inc. (HROW)

Over the past six months, Harrow's stock experienced fluctuations influenced by key events and financial reports. In Q2 2025, Harrow reported record revenues and announced securing U.S. rights to two ophthalmic biosimilars. An Investor Day was held in September 2025. In Q3 2025, Harrow's EPS beat analyst estimates, but quarterly revenue was below estimates. Harrow reaffirmed its full-year 2025 revenue guidance and announced commercial expansion plans. ImprimisRx exited the California market. Harrow Health shares saw mixed sentiment due to positive analyst coverage and a high debt-to-equity ratio.

Demand for Harrow, Inc.'s products exhibits seasonality. The first quarter is historically the weakest revenue period due to patient deductibles resetting. The fourth quarter is typically strong due to distributors stocking up at year-end. Despite quarterly fluctuations, customer unit demand for Harrow's products shows an upward trend. Products like IHEEZO and VEVYE have shown strong and accelerating demand.

Harrow, Inc. is an eyecare pharmaceutical company focused on the North American market, operating in the drug manufacturers - specialty & generic industry. They offer prescription and non-prescription ophthalmic products under the Harrow name and own ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. Major products include IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, NEVANAC, FLAREX, MAXIDEX, NATACYN, ZERVIATE, BYQLOVI, TOBRADEX ST, VERKAZIA cyclosporine ophthalmic emulsion, FRESHKOTE preservative free (PF), BYOOVIZ® and OPUVIZ™.

Harrow, Inc. primarily focuses on the North American market. ImprimisRx serves patients and providers in 49 U.S. states, having exited the California market. Harrow continues to serve the California market with its branded products and is headquartered in Nashville, Tennessee.

Harrow's brand reputation has been largely positive, driven by successful product launches and strategic growth initiatives. The successful rollout of VEVYE and strong financial performance have contributed to a positive reputation. Strategic acquisitions and partnerships, such as the acquisition of U.S. rights to ophthalmic biosimilars, have enhanced Harrow's offerings. The company's commitment to patient care also contributes to a positive brand image. The ImprimisRx California exit could have a minor impact on the reputation of its compounding division.

Harrow, Inc.'s ownership includes institutional, retail, and individual investors. Institutional investors hold a significant percentage of shares, with major holders including Opaleye Management Inc., BlackRock, Inc., and Vanguard Group Inc. Individual investors and public companies own a notable portion of the stock. Insiders, including Mark L. Baum, Daniel Louis Kaufman, and Andrew R. Boll, also hold a substantial stake.